This week we leave Copenhagen but stay in Scandinavia, pass through Norway and arrive at this week’s destination, Finland. This country is famous being the home of Santa Claus (very fitting for this time of year), it’s large number of heavy metal bands and for inventing the sauna. It is also the residence of our biotech of the week: Forendo Pharma.
City: Turku, Finland
Employees: 11-49 (12/15)
Financial Data: €12M Total Raised (12/15)
Mission: Forendo Pharma is a privately held pharma company that primarily focuses on tissue specific hormone mechanisms, notably secondary hypogonadism in males and endometreosis. Its 2 main products are fispemifene, a novel estrogen receptor modulator, which is used to treat secondary hypogonadism by restoring the circulating testosterone within normal ranges. This drug currently has promising data from it’s phase II results. The second product, HSD17B1-inhibitor, focuses on treating endometriosis by inhibiting the HSD17B1 enzyme,